The abstract is read at the publisher; the summary is JClub's.
Adding the ivWatch IV biosensor to standard observation is being tested in infants under 1 year with PIVCs expected to last over 24 hours, targeting reduced infiltration/extravasation injuries.
- Why it matters: Up to 20% of hospitalised infants with a PIVC have an infusate-related injury, and the trial addresses whether biosensor-supported observation can reduce these harms while also informing implementation.
- What they did: PATCH is a multicentre type 1 hybrid effectiveness-implementation RCT across three Queensland hospitals, randomising eligible infants 1:1 (n=532 target) and stratifying by site using logistic regression adjusted for randomisation stratum.
- The result: The primary outcome is any infiltration/extravasation injury (mild to severe harm on the CCHMC Extravasation Harm Scale) confirmed by a blinded committee, with risk difference estimated by standardisation and odds ratio reported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.